Mithra Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Liege Belgium (1999)
Status: Left NME R&D (2016)

Organization Overview

First Clinical Trial
2010
NCT00989443
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (3)

Key: Mithra Pharmaceuticals (0) Acquired (3)

drospirenone (Yasmin) (8 trials)

estetrol (NEXTSTELLIS) (13 trials)

progesterone (progestasert) (1 trial)

Drugs in Phase 2 Trials (5)

Key: Mithra Pharmaceuticals (1) Acquired (4)

dactinomycin (cosmegen) (1 trial)

estradiol (progynon depot) (3 trials)

ethinyl estradiol (Estinyl) (2 trials)

norgestrel (Ovral) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 1 Trials (3)

Key: Mithra Pharmaceuticals (1) Acquired (2)

cidofovir (vistide) (1 trial)

moxifloxacin (avelox) (1 trial)

valproic acid (depakene) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cervical Intraepithelial Neoplasia (Phase 2)

Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 16
  • # of Trial APIs: 11